Mirxes Completes $87 Million Series C Round to Develop Early Cancer Screening Products Based on Leading miRNA Technology
Focused on microRNA technology, dedicated to early disease diagnosis.
@gaorong
创造美好生活
Focused on microRNA technology, dedicated to early disease diagnosis.
Accelerate the development of data-factor circulation infrastructure.
Consumer investment is returning to natural consumer demand, and medical technology innovation is emerging.
The business covers South Asia, Southeast Asia, Greater China, and Latin America, among other regions.
How to "scientifically" improve an organization.
Focusing on novel process innovation to create products that actually deliver results.
Developing advanced sensing chips for industry, creating "eyes of insight" for the future.
Accelerating the development of globally leading first-in-class drugs.
Make innovative technology accessible to more people.
Providing high-power and high-frequency VCSEL solutions for customers worldwide.